학술논문

Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report
Document Type
article
Source
Personalized Medicine.
Subject
Biomedical and Clinical Sciences
Clinical Sciences
BRAF V600E
central nervous system
CNS
corticosteroids
dabrafenib
Erdheim-Chester Disease
histiocytosis
orbit
pachymeninges
steroids
Pharmacology & Pharmacy
Clinical sciences
Pharmacology and pharmaceutical sciences
Language
Abstract
Erdheim-Chester disease (ECD) is an exceedingly rare non-Langerhans cell CD68+ CD1a- S100- histiocytic multi-organ disease. Diagnosis of ECD is often delayed due to non-specific radiographic findings and heterogeneous lesional tissue. Increasingly, the role of genomic alterations is being recognized for both diagnosis and treatment of ECD. More than half of ECD patients harbor the BRAFV600E mutation. Evaluation for this mutation be can falsely negative on immunohistochemical staining and confirmation with molecular analyses is recommended. We present a case of the 44 year-old male with BRAFV600E-positive ECD treated successfully with steroids followed by single-agent dabrafenib.